Autopsy report · NCT00642733

A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

“poor recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months after it had already started.
• Ran for about 1 year 8 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Pancreatic Cancer

Interventions

erlotinib [Tarceva]; gemcitabine

Participants

6

Sites

2

Countries

Mexico

Trials that died the same way

• Pilot RCT Evaluating a One Stop Vein Clinic
  “Very poor recruitment” (95% match in meaning)
• Prospective Evaluation of Quality of Life in Patients With Acute Colonic Diverticular Disease
  “poor recruitment status” (93% match in meaning)
• Expanding Access to Comprehensive Geriatrics Care Via Telehealth
  “Inadequate recruitment” (92% match in meaning)
• Is Interval Appendectomy Necessary?
  “Low recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.